Results 41 to 50 of about 86,826 (247)
ABSTRACT Doxorubicin‐induced cardiomyopathy (DIC) remains a dose‐limiting clinical challenge. This study reveals that cardiac vascular endothelial cells (CVECs) act as initial sensors of doxorubicin cardiotoxicity: circulating doxorubicin activates the cGAS‑STING pathway in CVECs, triggering NLRP3 inflammasome‑mediated pyroptosis and release of ...
Wang Jun +10 more
wiley +1 more source
ABSTRACT High‐fat diet (HFD)‐induced hepatic injury represents a pathology observed across vertebrates, yet the underlying mechanisms remain incompletely understood. Herein, the present study identifies phosphatidylethanolamine methyltransferase (Pemt), a key enzyme in phosphatidylcholine synthesis, as a critical regulator of mitochondrial homeostasis ...
Xianyong Bu +11 more
wiley +1 more source
Spontaneous Tumor Lysis Syndrome in a Patient with Metastatic Small Cell Lung Cancer: A Case Report
Tumor lysis syndrome is an oncologic emergency that usually occurs after chemotherapy in patients with hematologic malignancies. Tumor lysis syndrome is rare in cases of solid tumors, especially when it occurs spontaneously.
Boonphiphop Boonpheng +2 more
doaj +1 more source
Hypercalcemia in Tumor Lysis Syndrome [PDF]
Tumor lysis syndrome (TLS) is characterized by hyperkalemia, hyperuricemia, hypocalcemia and hyperphosphatemia. This report describes a case of hypercalcemia in TLS in a patient with diffuse large B cell lymphoma.
openaire +2 more sources
Tumor‐derived GDF15 drives cancer cachexia and suppresses antitumor immunity. Here, de novo designed minibinders targeting the GDF15–GFRAL interface achieve picomolar affinity and potent pathway blockade. The minibinders alleviate cachexia, restore CD8+ T‐cell infiltration, enhance anti–PD‐1 responsiveness, and provide survival benefits across tumor ...
Haitao Wang +8 more
wiley +1 more source
Plasma cell leukemia presenting as spontaneous tumor lysis syndrome with hypercalcemia
Tumor lysis syndrome (TLS) is an oncologic emergency in which tumor cells undergo lysis either spontaneously or due to the initiation of cancer therapy typically presenting with hypocalcemia.
Mahan Shafie +3 more
doaj +1 more source
Tumor lysis syndrome in pediatric patients with hematological malignancies
BACKGROUND: Tumor lysis syndrome (TLS) is a common complication of hematological malignancies and consists of either hyperkalemia, hyperphosphatemia, hyperuricemia, or hypocalcemia. These metabolic derangements may result in clinical tumor lysis syndrome
Lamis Hani Elkhatib +5 more
doaj +1 more source
UBE2O targets CDKL1 for the degradation to upregulate PD‐L1 expression and promotes resistance to radioimmunotherapy in lung cancer, supporting the potential of targeting UBE2O as a promising therapeutic strategy. ABSTRACT Resistance to radioimmunotherapy is one of the primary causes of treatment failure in lung cancer patients; however, the underlying
Huichan Xue +6 more
wiley +1 more source
This study reveals a novel GC therapy targeting cholesterol homeostasis. Inhibiting the SCAP sterol‐sensing domain causes lethal ER stress via cholesterol accumulation, paradoxically forcing continuous synthesis that triggers ferroptosis. The findings link sterol sensing, metabolic dysregulation, and ferroptosis, establishing an anti‐cancer paradigm ...
Qianqian Xu +17 more
wiley +1 more source
Prevention, diagnosis and treatment of tumor lysis syndrome
Tumor lysis syndrome (TLS) is an acute, life-threatening condition that occurs either spontaneously or as a complication of cytoreductive antitumor therapy, and occurs in both children and adults. As a result of TLS, intracellular components are released
Michał Piwoński +3 more
doaj +1 more source

